Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammatory Disease and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for RHBDF2 (iRhom2) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Full-Length Membrane Protein) | RHBDF2 Full-Length Membrane Protein, HEK293 Expressed (Native Conformation), Detergent Solubilized, Purity >90% (SDS-PAGE), Endotoxin <1EU/µg, Sequence Verified. | View RHBDF2 Products |
| Antigen (ECD-Fc / Mutant) | RHBDF2 ECD-Fc / Mutant Protein, High purity (>95%), Endotoxin <1EU/µg, Sequence Verified. | View RHBDF2 Products |
| Gene Delivery | RHBDF2 Lentivirus Premade Particles (High Titer >10^8 TU/mL, Puromycin Selection, Full-length ORF) for Stable Cell Line Generation (Flow Cytometry/Co-IP Ready). Also available as Promise-ORF clone. | View RHBDF2 Products |
| Benchmark Ab | Anti-RHBDF2 (Clone iRhom2-1) Recombinant Antibody, Sequence Verified Positive Control for Western Blot and IP. | View RHBDF2 Products |
| Validator | RHBDF2 siRNA Set (3 unique targets) for knockdown verification and specificity controls. | View RHBDF2 Products |
| Related Target: ADAM17 | ADAM17 (TACE) Recombinant Protein – critical binding partner for P-P interaction assays. | View ADAM17 Products |
| Related Target: RHBDF1 | RHBDF1 (iRhom1) Protein & Lentivirus – essential for selectivity screening (paralog discrimination). | View RHBDF1 Products |
| Related Target: EGFR | EGFR Recombinant Protein – regulated via RHBDF2-dependent AREG release. | View EGFR Products |
Critical Assay Requirements & Technical Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Protein-Protein Interaction (iRhom2-ADAM17) Validation | Full-length RHBDF2 Lentivirus for physiological membrane insertion; Native folding verified by ADAM17 co-immunoprecipitation. |
| Cross-Species Preclinical Translation (Cyno/Mouse) | Human/Mouse/Cynomolgus RHBDF2 ortholog proteins available with >95% sequence identity coverage. |
| Paralog Selectivity (vs RHBDF1/iRhom1) | Strictly verified RHBDF1 and RHBDF2 protein pairs for off-target counter-screening. |
| Specificity Controls | Gene-specific siRNA sets included for target engagement confirmation. |
| Cell Surface Trafficking Assays | High-titer lentivirus enables stable GFP/RFP fusion cell lines for quantitative flow cytometry. |
| Complex Membrane Conformation (Multi-pass) | Lentivirus Premade Particles for robust stable cell line construction. |
| Lack of Controls | Reference Antibodies (Biosimilars) included for assay benchmarking. |
| False Positives in Cellular Assays | Validated siRNA included for absolute specificity checks. |
Live RHBDF2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for RHBDF2 (iRhom2) therapeutics represents a paradigm shift in sheddase-targeting strategies. Direct inhibition of ADAM17 (TACE) failed in the clinic due to severe systemic toxicities from broad metalloprotease inhibition. RHBDF2 has emerged as a safer, context-specific regulator of ADAM17 trafficking, controlling TNF-alpha secretion in immune cells and EGFR ligand shedding in epithelial tumors. Current discovery efforts focus on disrupting the iRhom2-ADAM17 protein-protein interaction to selectively block TNF-alpha and EGFR ligand shedding without affecting constitutive ADAM17 activity. Key therapeutic applications include inflammatory bowel disease (IBD), psoriasis, adolescent acne, rheumatoid arthritis, and EGFR-driven solid tumors where resistance stems from ligand-independent receptor activation. As first-generation therapies reach preclinical maturation, the next wave of R&D targets combination strategies with anti-TNF biologics, small molecule PPI disruptors, and selective trafficking modulators. Additionally, PROTAC/degrader approaches are emerging for severe inflammation and fibrosis. The ultimate goal is to achieve oral bioavailability and superior safety over traditional biologics.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Blocking mAb (Anti-iRhom2) | MRC Technology, Academic Consortia, Early-stage Biotech | IBD, Psoriasis, Solid Tumors | Surface Expression Assay (Requires Lentivirus-stable cells); Binding Assays (Need high-purity ECD-Fc with Native Glycosylation) |
| Small Molecule (PPI Disruptor) | Academic Spin-offs, Biotech Innovators, Preclinical Biotech | Rheumatoid Arthritis, IBD, Oncology (EGFR-driven) | iRhom2-ADAM17 Binding Assay (Full-length proteins); Selectivity Assay (RHBDF1 vs RHBDF2 Lentiviral cell lines) |
| Selective Trafficking Disruptor | Early Discovery | Acne, Inflammation | RHBDF1 vs RHBDF2 Selectivity Panel |
| PROTAC / Degrader | Preclinical Discovery Labs | Fibrosis, Severe Inflammation | Degradation Validation (Need Sequence-Verified Reporter Assays) |